Medical technology plays a key role in health and makes a contribution to improving quality of life. The spectrum of medical technology ranges from disposable products, IT-based applications to innovative technologies. In Baden-Württemberg, 836 companies are active in research, development and/or production in this field, making medical technology one of the most important economic sectors in the state.

Baden-Württemberg is currently home to 193 biotechnology companies, most of which specialise in so-called ‘red biotechnology’ - i.e. applications in the medical and pharmaceutical sectors. The biotech sector includes not only traditional biotechnology companies, but also companies from the fields of bioinformatics, diagnostics, analytics and biotechnological production.

Baden-Württemberg is the leading location for the pharmaceutical industry in Germany. In addition to international industry giants such as Roche, Pfizer and Boehringer Ingelheim, numerous medium-sized pharmaceutical companies and innovative biotechnology companies specialising in pharmaceutical research and development are also based in this region.

Dossier - 09/02/2015

Chemical tools for biological applications

The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology.

Dossier - 10/11/2014

Cell and gene therapies from bench to bedside

While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.

Dossier - 30/06/2014

Addiction new concepts for resolving old problems

Addictive substances and behaviours are as varied as their effects on an addict’s health and personality. However, modern neurobiological research has revealed common principles in the development and continuation of addiction, which can be used as an approach for new prevention and therapy strategies including the prevention of relapses. This dossier presents some of the latest research results in the field.

Dossier - 28/04/2014

Data mining new opportunities for medicine and public health

Research and healthcare activities produce huge quantities of data that need to be presented in an understandable structure. This requires computer-assisted extraction of relevant data and the use of statistical methods. This process, known as data mining, enables the discovery of patterns in large data sets. Data mining methods are of particular importance in fields that use high-throughput, visualisation methods and telemedical applications.

Dossier - 31/03/2014

Peptides diverse molecules of life

Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Peptides are gaining in importance as candidates for drugs.

Dossier - 10/02/2014

Multiresistant pathogens a self-inflicted threat?

Most bacterial infections have lost their capacity to cause terror thanks to antibiotics. However, the increase in antibiotic resistances is making the fight against bacterial pathogens rather difficult, and the widespread overuse and inappropriate use of antibiotics continues to fuel the increase in antibiotic-resistant bacteria.

Dossier - 20/01/2014

Optogenetics switching cell activity on and off with light

What still sounds like science fiction to the general public has long been within reach for many years scientists have been able to manipulate neural activity selectively with light. They use different wavelengths to turn cells on and off as if they were a standard switch. Optogenetics is an emerging technology that combines optics and genetics. The technology is already used in many different ways for many different purposes by numerous research…

Dossier - 02/12/2013

RNA interference confidence is returning

The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

Dossier - 18/11/2013

Innovative textiles made possible by biotechnology

Biotechnology plays a part in many high-tech fabrics that have become an integral part of our everyday life. Whether it is products for the treatment of wounds, fabrics for marquees or for clothing, many materials have been developed or are produced using biotechnological techniques and processes. Many products marketed as “micro” or “nano” are inspired by nature.

Dossier - 04/11/2013

Biotechnology driver of innovation in the pharmaceutical industry

The biotech industry is the innovative driver for a pharmaceutical industry that, due to the shift from blockbluster products to personalised medicine, now depends on new concepts. The production of new drugs using genetic engineering relies on knowledge gained from genomics, proteomics and systems biology and creates new treatment strategies that combine therapy and diagnostics (i.e. companion diagnostics) to provide a specific individualised…

Dossier - 15/10/2013

Adult stem cells hope for regenerative therapies

Adult stem cells have the lifelong ability to generate new specialised cells. They secure the continuous replenishment of cells therefore enabling the constant replacement of dying cells with new ones. Progress in the characterisation isolation and specific differentiation of adult stem cells over recent years raises hopes for the future use of the cells in the therapy of degenerative diseases. Knowledge about adult stem cells also has the…

Dossier - 19/08/2013

Telemedicine advances in high-tech healthcare

Increasing average longevity, the growing number of chronic diseases and health economy issues are all generating an ever-increasing demand for inexpensive therapy options that are not time - or location dependent. Telemedicine has been offering advanced solutions for a broad range of medical and health issues. Despite this progress, the use of telecommunication and information technologies in the provision of remote healthcare services appears…

Dossier - 05/08/2013

Progress expands bioethical boundaries

Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. Rapid progress in genetic engineering and cell biology means that it is necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be carried out.

Dossier - 03/06/2013

Food analytics applied consumer protection

Consumers rightly expect to be supplied with healthy, high-quality and safe foods. However, over the past few years, food scandals have frequently hit the headlines. They are brought to light in laboratories that have a huge arsenal of methods and procedures to analyse food. Although the media would have us believe otherwise, the vast majority of foods are safe and very rarely hazardous to human health.

Dossier - 21/05/2013

No new drugs to be placed on the market without clinical trials

New pharmaceuticals are subject to approval by drug authorities. Here clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the drug. The costs including failures can amount to approximately one billion US dollars per drug.

Dossier - 05/11/2012

Cancer basic research successes and trends

Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.